v3.26.3
SEGMENT REPORTING (Tables)
9 Months Ended
Sep. 30, 2026
SEGMENT REPORTING  
Schedule of Additional disaggregated significant segment expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30

​

Nine Months Ended September 30

​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

R&D Employee Expenses

$

2,804

 

$

1,635

 

$

6,832

 

$

4,991

R&D Clinical Trial Expenses

​

2,221

 

​

1,736

​

​

5,388

 

​

4,377

R&D Manufacturing

​

545

​

​

402

​

​

2,140

​

​

1,234

R&D License Fees

​

21,801

​

​

2,000

​

​

21,801

​

​

2,438

G&A Professional Fees

​

2,285

​

​

1,116

​

​

4,979

​

​

4,118

G&A Employee Expenses

​

672

​

​

472

​

​

1,841

​

​

1,446

G&A Insurance and other

​

722

​

​

432

 

​

1,526

​

​

1,326

Other Segment Items *

​

(980)

 

​

(331)

 

​

(1,367)

 

​

(802)

Segment Loss

$

30,070

 

$

7,462

​

$

43,140

 

$

19,128

​

* - Other Segment Items included in net loss include finance income.